CLAIMS

1. An immunogenic composition comprising an immune checkpoint inhibitor, and a recombinant attenuated *Listeria* strain comprising a nucleic acid molecule, said nucleic acid molecule comprising a first open reading frame encoding a fusion polypeptide, wherein said fusion polypeptide comprises a truncated Listeriolysin O protein, a truncated ActA protein, or a PEST amino acid sequence fused to a heterologous antigen or fragment thereof.
2. An immunogenic composition comprising a T-cell stimulator, and a recombinant attenuated *Listeria* strain comprising a nucleic acid molecule, said nucleic acid molecule comprising a first open reading frame encoding a fusion polypeptide, wherein said fusion polypeptide comprises a truncated Listeriolysin O protein, a truncated ActA protein, or a PEST amino acid sequence fused to a heterologous antigen or fragment thereof.
3. An immunogenic composition comprising an immune checkpoint inhibitor, a T-cell stimulator, and a recombinant attenuated *Listeria* strain comprising a nucleic acid molecule, said nucleic acid molecule comprising a first open reading frame encoding a fusion polypeptide, wherein said fusion polypeptide comprises a truncated Listeriolysin O protein, a truncated ActA protein, or a PEST amino acid sequence fused to a heterologous antigen or fragment thereof.
4. The composition of claims 1-3, wherein said nucleic acid molecule is integrated into the *Listeria* genome.
5. The composition of claims 1-3, wherein said nucleic acid molecule is in a bacterial artificial chromosome in said recombinant *Listeria* strain.
6. The composition of claims 1-3, wherein said nucleic acid molecule is in a plasmid in said

recombinant *Listeria* strain.

7. The composition of claim 6, wherein said plasmid is stably maintained in said recombinant *Listeria* strain in the absence of antibiotic selection.
8. The composition according to any one of claims 6 and 7, wherein said plasmid does not confer antibiotic resistance upon said recombinant *Listeria* strain.
9. The composition according to any of the claims 1-8, wherein said heterologous antigen is a tumor-associated antigen.
10. The composition according to claim 9, wherein said tumor-associated antigen is a a human papilloma virus (HPV).
11. The composition of claim 9, wherein said tumor-associated antigen is an angiogenic antigen.
12. The composition according to any of the claims 1-11, wherein said recombinant *Listeria* strain is attenuated.
13. The composition of claim 12, wherein said attenuated *Listeria* strain comprises a mutation in an endogenous gene.
14. The composition of claim 13, wherein said recombinant *Listeria* strain comprises a mutation in the endogenous *actA* virulence gene.
15. The composition of any one of claims 13-14, wherein said recombinant *Listeria* strain comprises a mutation in the endogenous *prfA* gene.
16. The composition of claim 15, wherein said *prfA* mutation is a D133V mutation.
17. The composition of any one of claims 13-16, wherein said recombinant *Listeria* strrain comprises a mutation in the endogenous D-alanine racemase (*dal*) and D-amino acid transferase (*dat*) genes.

18. The composition accordling to claims 13-15 and 17, wherein said mutation comprises an inactivation, truncation, deletion, replacement or disruption of the gene.
19. The composition according to any one of claims 1-18, wherein said nucleic acid molecule further contains a second open reading frame.
20. The composition of claim 19, wherein said second open reading frame encodes a metabolic enzyme.
21. The composition according to claim 20, wherein said metabolic enzyme encoded by said second open reading frame is an alanine racemase enzyme or a D-amino acid transferase enzyme.
22. The composition according to claims 1 and 3-21, wherein said immune checkpoint inhibitor is a PD-1 signaling pathway inhibitor, a CD-80/86 and CTLA4 signalling pathway inhibitor, a T cell membrane protein 3 (TIM3) signalling pathway inhibitor, an adenosine A2a receptor (A2aR) signalling pathway inhibitor, a lymphocyte activation gene 3 (LAG3) signalling pathway inhibitor, or a killer immunoglobulin receptor (KIR) signalling pathway inhibitor.
23. The composition of claim 22, wherein said PD1 signaling pathway inhibitor is a molecule blocking PD-1 receptor interactions with PD-1 Ligand 1 (PD-L1) and PD-1 Ligand 2 (PD-L2).
24. The composition of claim 23, wherein said molecule blocking PD-1 receptor interactions with PD-1 Ligand 1 (PD-L1) and PD-1 Ligand 2 (PD-L2) is a molecule interacting with PD-1, PD-L1 or PD-L2.
25. The composition of claim 24, wherein said molecule interacting with PD-1 is an anti-PD-1 antibody.

26. The composition of claim 24, wherein said molecule interacting with PD-1 is a truncated PD-L1 protein or a truncated PD-L2 protein.
27. The composition of claim 26, wherein said truncated PD-L1 protein comprises the cytoplasmic domain of PD-L1 protein.
28. The composition of claim 26, wherein said truncated PD-L2 protein comprises the cytoplasmic domain of PD-L2 protein.
29. The composition of claim 24, wherein said molecule interacting with PD-L1 is an anti-PD-L1 antibody, a truncated PD-1 protein, a PD-1 mimic, or a small molecule that binds PD-L1.
30. The composition of claim 24, wherein said molecule interacting with PD-L2 is an anti-PD-L2 antibody, a truncated PD-1 protein, a PD-1 mimic, or a small molecule that binds PD-L2.
31. The composition of claim 24, wherein said molecule interacting with PD-1L and PD-2L is a truncated PD-1 protein.
32. The composition of claim 31, wherein said truncated PD-1 protein comprises the cytoplasmic domain of PD-1 protein.
33. The composition according to any one of claims 2-21, wherein said T-cell stimulator is an an antigen presenting cell (APC)/ T cell agonist.
34. The composition of claim 33, wherein said agonist is a CD134 or a ligand thereof or a fragment thereof, CD-137 or a ligand thereof or a fragment thereof, or an Includible T cell costimulator (ICOS) or a ligand thereof or a fragment thereof.
35. The composition according to any of claims 1-34, further comprising an adjuvant.
36. The composition of claim 35, wherein said adjuvant comprises a

granulocyte/macrophage colony-stimulating factor (GM-CSF) protein, a nucleotide molecule encoding a GM-CSF protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide.

37. Use of a composition according to any of the claims 1, and 4-36 in the manufacture of a medicament for eliciting an enhanced anti-tumor T cell immune response in a subject.

38. Use of a composition according to any of the claims 2 and 4-36 in the manufacture of a medicament for eliciting an enhanced anti-tumor T cell immune response in a subject.

39. Use of a composition according to any of the claims 3-36 in the manufacture of a medicament for eliciting an enhanced anti-tumor T cell immune response in a subject.

40. The use of any one of claims 37-39, wherein said immune response comprises increasing a level of interferon-gamma producing cells.

41. The use of any one of claims 37-39, wherein said immune response comprises an increase of tumor infiltration by T effector cells.

42. The use of claim 41, wherein said T effector cells are CD45+CD8+Tcells or CD4+Fox3P- T cells.

43. The use of any one of claims 37-39, wherein said immune response comprises a decrease in the frequency of T regulatory cells (Tregs) in the spleen and the tumor microenvironment.

44. The use of any one of claims 37-39, wherein said immune response comprises a decrease in the frequency of myeloid derived suppressor cells (MDSCs) in the spleen and the tumor microenvironment.

45. Use of a composition according to any of the claims 1, and 4-36 in the manufacture of a medicament for inhibiting tumor-mediated immunosuppression in a subject.

46. Use of a composition according to any of the claims 2, and 4-36 in the manufacture of a medicament for inhibiting tumor-mediated immunosuppression in a subject.

47. Use of a composition according to any of the claims 3-36 in the manufacture of a medicament for inhibiting tumor-mediated immunosuppression in a subject.

48. Use of a composition according to any of the claims 1, and 4-36 in the manufacture of a medicament for increasing the ratio of T effector cells to regulatory T cells (Tregs) in the spleen and tumor of a subject.

49. Use of a composition according to any of the claims 2, and 4-36 in the manufacture of a medicament for increasing the ratio of T effector cells to regulatory T cells (Tregs) in the spleen and tumor of a subject.

50. Use of a composition according to any of the claims 3-36 in the manufacture of a medicament for increasing the ratio of T effector cells to regulatory T cells (Tregs) in the spleen and tumor of a subject.

51. The use according to any one of claims 37-50, wherein the composition is administered with, prior to, or after the admistration of a cytokine that enhances said anti-tumor immune response.

52. The use of claim 51, wherein said cytokine is: a type I interferon (IFN-α / IFN-β), TNF-α, IL-1, IL-4, IL-12, INF-γ.

53. The use according to any one of claims 37-50, wherein the composition is administered with, prior to, or after the administration of a tumor kinase inhibitor (TKI) that enhances said anti-tumor immune response.

54. The use of claim 53, wherein said TKI is selected from Table 1.

55. The use according to any one of claims 37-50, wherein the composition is administered

with, prior to, or after the administration of an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor.

56. The use of claim 55, wherein said IDO pathway inhibitor is a small molecule that binds or interacts with IDO, or an anti-IDO antibody.

57. The use according to any one of claims 37, 39-41,43-45, 47-48, and 50-56, wherein the checkpoint inhibitor comprised by the composition is administered to the subject before, concurrently with, or after the administration of the recombinant *Listeria* strain.

58. The use according to any one of claims 38, 40-44, 46-47, and 50-56, wherein the T-cell stimulator comprised by the composition is administered to the subject before, concurrently with, or after the administration of the recombinant *Listeria* strain.

59. The use according to any one of claims 39-44, 47, and 50-56, wherein the T cell stimulator and the checkpoint inhibitor comprised by the composition are administered to the subject before, concurrently with, or after the administration of the recombinant *Listeria* strain.

60. The use according to any of claims 37-50 and 57-59, wherein the medicament comprises a booster dose of the composition, the recombinant *Listeria*, the T cell stimulator or the checkpoint inhibitor to the subject.

61. The use according to any one of claims 37-60, wherein the use further comprises treating a tumor or cancer in a subject.

62. The use according to any one of claims 37-60, wherein the use further comprises preventing a tumor growth or cancer in a subject.